文献速递瓣膜外科

ICE-AFIB试验:心脏手术同期冷冻消融治疗房颤的多中心前瞻性IDE研究

The ICE-AFIB trial: A multicenter prospective investigational device exemption (IDE) trial using cryosurgical ablation for atrial fibrillation during concomitant cardiac surgery.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-10-23

ICE-AFIB是首个评估冷冻作为唯一能量源行同期Cox-maze III术治疗非阵发性房颤的前瞻性多中心IDE试验。

要点

  • 冷冻消融同期Cox-maze III术6-12个月无房颤/房扑/房速率为70%。
  • 12个月停用I/III类抗心律失常药后无房颤/房扑/房速率为77%。
  • 30天主要不良事件率为9.3%,均与手术消融/装置无关。

核心结论

  • ICE-AFIB试验表明,对持续性和长程持续性房颤患者,单次手术仅用冷冻能源行Cox-maze术是安全有效的。

研究设计与样本

  • ICE-AFIB为单臂、贝叶斯自适应设计、IDE研究(NCT03732794)。

主要发现

  • 主要有效性:术后6至12个月无房颤/房扑/房速率为70%(后验概率0.9997;95%可信区间62%-77%)。
  • 12个月停用I/III类抗心律失常药后无房颤/房扑/房速率为77%(95%置信区间68.7%-84.5%)。
  • 30天主要不良事件率为9.3%(后验概率0.974;95%可信区间14.2%),包括卒中2.7%、大出血5.3%、手术死亡2%,均与手术消融/装置无关。

关键数值与推荐

  • 主要有效性定义为术后6至12个月无房颤/房扑/房速。
  • 主要安全性定义为30天内复合主要不良事件(心肌梗死、卒中、大出血、死亡)率。

临床怎么用

  • 对于接受心脏手术的持续性和长程持续性房颤患者,可考虑同期使用冷冻能源行Cox-maze III术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Surgical treatment for atrial fibrillation (AF) has transitioned from cut-and-sew to cryothermal and radiofrequency ablation. ICE-AFIB is the first prospective, multicenter investigational device exemption trial to evaluate cryothermy as a sole energy source to perform concomitant Cox-maze III procedures for patients with nonparoxysmal AF. METHODS: ICE-AFIB is a single-arm, Bayesian adaptive design, investigational device exemption study (NCT03732794). Patients ≥18 years with persistent/longstanding persistent atrial fibrillation underwent concomitant cryosurgical Cox-maze III. Primary effectiveness was freedom from AF/atrial flutter/atrial tachycardia from 6 to 12 months after the procedure. Primary safety was composite major adverse event (myocardial infarction, stroke, major bleeding, death) rate within 30 days. Rhythm assessment was with periodic 24-hour Holter monitoring. RESULTS: One hundred fifty patients were treated at 14 sites, with median age 69.0 (standard deviation [SD], 8.85) years, median body mass index 31.0 (SD 6.90) kg/m2, CHA2DS2-VASc = 3.0 (SD 1.67), and median left atrial diameter 5.2 (SD 0.83) cm. In total, 66.0% were male, and median current/most recent AF episode was 5.7 (SD 25.86) months in duration (63.3% persistent AF, 36.7% long-standing persistent AF). Concomitant procedures were mitral valve (67.3%), tricuspid valve (42.0%), coronary artery bypass grafting (29.3%), and aortic valve (18.7%); 59.3% had multiple concomitant procedures. Primary effectiveness was met with 70% freedom from AF/atrial flutter/atrial tachycardia from 6 through 12-months (posterior probability: 0.9997; 95% credible interval, 62%-77%) and 77% (95% confidence interval, 68.7%-84.5%) at 12 months off class I/III AADs. Primary safety at 30 days was achieved with a major adverse event rate of 9.3% (posterior probability: 0.974; 95% credible interval, 14.2%), including 2.7% stroke, 5.3% major bleeding, 2% operative mortality, all unrelated to surgical ablation/device. CONCLUSIONS: The ICE-AFIB trial demonstrated safety and effectiveness of single procedure cryothermal-only cryomaze procedure in patients with persistent and longstanding persistent atrial fibrillation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ad N, Romano MA, Bolling S, et al. The ICE-AFIB trial: A multicenter prospective investigational device exemption (IDE) trial using cryosurgical ablation for atrial fibrillation during concomitant cardiac surgery. J Thorac Cardiovasc Surg. 2025. PMID: 41138810. doi:10.1016/j.jtcvs.2025.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。